['cardiorenal syndrome']
['levosimendan', 'dobutamine']

        Inclusion Criteria:

          -  Written, signed and dated informed consent

          -  Male and Female subjects ≥18 years of age

          -  Chronic congestive heart failure scheduled for right sided cardiac catheterization

          -  Left ventricular ejection fraction ≤ 40% determined by echocardiography

          -  Elevation of N Terminal-proBNP ≥ 500 ng/L

          -  Cardiorenal syndrome (30ml/min ≤ estimated GFR ≤ 80 ml/min (MDRD)

        Exclusion Criteria:

          -  Acute heart failure, untreated

          -  Systolic blood pressure < 80 mmHg

          -  Tachycardia above 100 bpm

          -  Angina Canadian Cardiovascular Society (CCS) class III or higher

          -  Aortic stenosis

          -  Hypertrophic cardiomyopathy

          -  Restrictive cardiomyopathy

          -  The presence of kidney disease diagnosed before heart failure

          -  Administration of radiographic contrast < 1 week

          -  Radiographic contrast allergy

          -  In the Investigator's opinion, the patient has a clinically significant disease that
             could be adversely affected by study participation
      